Fredrik Öberg
Adjunct Professor at Department of Immunology, Genetics and Pathology; Research programme: Cancer Precision Medicine; Research group Helena Jernberg Wiklund
- E-mail:
- fredrik.oberg@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
Publications
Recent publications
-
Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma
Part of Blood Advances, p. 4825-4841, 2025
- DOI for Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma
- Download full text (pdf) of Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma
-
Part of Scientific Reports, 2025
- DOI for Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation
- Download full text (pdf) of Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation
-
Part of Haematologica, p. 567-577, 2024
- DOI for PVT1 interacts with the polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma
- Download full text (pdf) of PVT1 interacts with the polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma
-
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
Part of Cell Death and Disease, 2021
- DOI for A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
- Download full text (pdf) of A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
-
Part of Oncotarget, p. 10213-10224, 2017
- DOI for EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
- Download full text (pdf) of EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
All publications
Articles in journal
-
Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma
Part of Blood Advances, p. 4825-4841, 2025
- DOI for Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma
- Download full text (pdf) of Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma
-
Part of Scientific Reports, 2025
- DOI for Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation
- Download full text (pdf) of Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation
-
Part of Haematologica, p. 567-577, 2024
- DOI for PVT1 interacts with the polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma
- Download full text (pdf) of PVT1 interacts with the polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma
-
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
Part of Cell Death and Disease, 2021
- DOI for A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
- Download full text (pdf) of A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
-
Part of Oncotarget, p. 10213-10224, 2017
- DOI for EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
- Download full text (pdf) of EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
-
Part of Oncotarget, p. 103731-103743, 2017
- DOI for The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomain
- Download full text (pdf) of The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomain
-
Part of Oncotarget, p. 6809-6923, 2016
-
Part of Biochemical Pharmacology, p. 284-291, 2014
- DOI for AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and a dose dependent reduction of kinase activity in acute myeloid leukemia
- Download full text (pdf) of AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and a dose dependent reduction of kinase activity in acute myeloid leukemia
-
Part of Blood, 2014
-
Part of BMC Cancer, p. 318, 2012
- DOI for Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
- Download full text (pdf) of Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma
-
Polycomb target genes are silenced in multiple myeloma
Part of PLOS ONE, 2010
- DOI for Polycomb target genes are silenced in multiple myeloma
- Download full text (pdf) of Polycomb target genes are silenced in multiple myeloma
-
Herbal melanin activates TLR4/NF-kappaB signaling pathway
Part of Phytomedicine, p. 477-84, 2009
-
Part of Experimental Cell Research, p. 3099-3111, 2009
-
Positive histone marks are associated with active transcription from a methylated ICSBP/IRF8 gene
Part of Gene, p. 259-267, 2008
-
Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma
Part of Experimental Hematology, p. 1673-1681, 2008
-
Part of International Journal of Cancer, p. 189-195, 2007
-
Part of Molecular Immunology, p. 615-624, 2007
-
Part of International Journal of Cancer, p. 1577-1580, 2006
-
Part of Blood, p. 1346-1354, 2005
-
Part of Anti-Cancer Drugs, p. 45-54, 2004
-
Part of Thrombosis and Haemostasis, p. 930-9, 2003
-
Part of Blood, p. 254, 2003
-
Retinoic acid-induced cell cycle arrest of human myeloid cell lines.
Part of Leuk Lymphoma, p. 1641, 2003
-
Part of Blood, p. 2199, 2002
-
Part of Leukemia, p. 217-227, 2001
-
The role of RAR and RXR activation in retinoid-induced tissue factor suppression
Part of Leukemia, p. 1105-11, 2000
-
Part of Blood, p. 2870, 2000
-
Part of Blood, p. 3900-3912, 1999
-
Part of European Journal of Haematology, p. 112-119, 1999
-
Serglycin expression during differentiation of U937-1 cells
Part of Glycobiology, p. 747-753, 1998
-
Part of Journal of Biological Chemistry, p. 9443-9, 1997
- DOI for Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation
- Download full text (pdf) of Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation
-
Part of Leukemia, p. 142-4, 1997
-
Myeloperoxidase mediates cell adhesion via the alpha M beta 2 integrin (Mac-1, CD11b/CD18)
Part of Journal of Cell Science, p. 1133-1139, 1997
-
Tissue factor expression in human monocytic cell lines
Part of Thrombosis Research, p. 215-28, 1997
-
Part of Cell growth & differentiation, p. 1239-49, 1996
-
Part of Int. J. Cancer, p. 451, 1996
-
Part of Leukemia, p. 2034-41, 1995
Chapters in book
-
Stat1 involvement in retinoic acid induced differentiation of myeloid cells
Part of Molecular mechanisms of signal transduction, p. 211, IOS press, Amsterdam, The Netherlands, 2000
-
Part of Transplantation Biology, p. 241, Lippincott-Raven, 1996
Conference papers
-
Cytokine induced inhibition of Myc activity in monocytic cells
Part of C-myc in B-cell neoplasia, p. 191, 1997